OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-C

Désirée van der Heijde, Lianne S. Gensler, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Mary Katherine Farmer, Dominique Baeten, Jason Coarse, Marga Oortgiesen, Maxime Dougados. OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY. Oral Presentations. 2019 Jun 1; 193.1-193.